Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/185
Title: | A trial of extending hemodialysis hours and quality of life | Authors: | Gallagher, M. P. Eris, J. M. Lin, H. Chan, C. T. Monaghan, H. Grieve, S. M. Puranik, R. Perkovic, V. Cass, A. Zhang, L. Xu, J. Jardine, M. J. Lo, S. Gray, N. A. De Zoysa, J. R. Howard, K. Zuo, L. |
Issue Date: | 2017 | Source: | 28, (6), 2017, p. 1898-1911 | Pages: | 1898-1911 | Journal: | Journal of the American Society of Nephrology | Abstract: | The relationship between increased hemodialysis hours and patient outcomes remains unclear. We randomized (1:1) 200 adult recipients of standard maintenance hemodialysis from in-center and home-based hemodialysis programs to extendedweekly ($24 hours) or standard (target 12-15 hours, maximum18 hours) hemodialysis hours for 12 months. The primary outcome was change in quality of life from baseline assessed by the EuroQol 5 dimension instrument (3 level) (EQ-5D). Secondary outcomes included medication usage, clinical laboratory values, vascular access events, and change in left ventricularmass index. At 12months, median weekly hemodialysis hours were 24.0 (interquartile range, 23.6-24.0) and 12.0 (interquartile range, 12.0-16.0) in the extended and standard groups, respectively. Change in EQ-5D score at study end did not differ between groups (mean difference, 0.04 [95% confidence interval, 20.03 to 0.11]; P=0.29). Extended hours were associated with lower phosphate and potassium levels and higher hemoglobin levels. Blood pressure (BP) did not differ between groups at study end. Extended hourswere associatedwith fewer BP-lowering agents and phosphate-bindingmedications, but were not associated with erythropoietin dosing. In a substudy with 95 patients,wedetected no differencebetween groups in left ventricularmass index (meandifference,26.0 [95%confidenceinterval,214.8 to 2.7]g/m2;P=0.18).Fivedeaths occurred in the extended group and two in the standard group (P=0.44); two participants in each group withdrew consent. Similar numbers of patients experienced vascular access events in the twogroups. Thus, extendingweekly hemodialysis hours did not alter overall EQ-5D quality of life score, but was associated with improvement in some laboratory parameters and reductions in medication burden. (Clinicaltrials.gov identifier: NCT00649298).L617069886 | DOI: | 10.1681/ASN.2015111225 | Resources: | /search/results?subaction=viewrecord&from=export&id=L617069886http://dx.doi.org/10.1681/ASN.2015111225 | Keywords: | NCT00649298antianemic agent;hemoglobin;phosphate;potassium;adult;article;clinical laboratory;controlled study;diastolic blood pressure;female;heart left ventricle mass;hemodialysis;hemoglobin blood level;human;major clinical study;male;middle aged;outcome assessment;personal experience;phosphate blood level;potassium blood level;priority journal;prospective study;quality of life;quality of life assessment;randomized controlled trial;systolic blood pressure;vascular access | Type: | Article |
Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.